What’s new on therapies for elevated lipoprotein(a)

Ward, Natalie C.; Schultz, Carl; Watts, Gerald F.

doi:10.1080/17512433.2019.1610391

Search citation statements

Order By: Relevance

Paper Sections

Select...

Apo-(a)rx and Apo(a)-lrx (In Early Clinical Trials)2

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2019

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(2 citation statements)

References 68 publications

(67 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Lp(a) consists of a cholesterol-rich lipid particle, analogous to LDL, with apoB-100 linked by a disulphide bond to a highly glycosylated apoprotein, called apo(a) (71). While the apo(a) component is synthesized almost exclusively in the liver, the site of Lp(a) assembly has not been confirmed yet (72). Lp(a) clearance from plasma has an undefined mechanism, with the LDLR playing only a modest role.…”

Section: Apo-(a)rx and Apo(a)-lrx (In Early Clinical Trials)mentioning

confidence: 99%

“…In addition, five key classes of receptors have been described to play a role in the uptake of Lp(a), i.e. 'classical' lipoprotein receptors, scavenger receptors, toll-like receptors, carbohydrate receptors or lectins and plasminogen receptors (73); other possibilities include the proteolytic cleavage of apo(a) (72).…”

Section: Apo-(a)rx and Apo(a)-lrx (In Early Clinical Trials)mentioning

confidence: 99%

See 1 more Smart Citation